What is it about?
The patients who take atovastatins or rosuvastatins are at lower risk of NOF and that use of lovastatins were associated with a significantly increased risk of developing NOF during the ten-year follow up.
Featured Image
Why is it important?
We concluded that the patients who take atovastatins or rosuvastatins are at lower risk of NOF of developing NOF during the ten-year follow up.This study also highlighted that high-potency statin has a dose-response effect on lower NOF risk.
Perspectives
These findings emphasize the need for further investigation of the mechanistic links between these high potency statins and NOF.
Professor Gwo-Ping Jong
Chung Shan Medical University
Read the Original
This page is a summary of: High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study, Clinical Epidemiology, January 2018, Dove Medical Press,
DOI: 10.2147/clep.s145311.
You can read the full text:
Contributors
The following have contributed to this page
